Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986278 Batched method, Dose A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1, Sequence 1 | EXPERIMENTAL | - |
| Part 1, Sequence 2 | EXPERIMENTAL | - |
| Part 2, Sequence 1 | EXPERIMENTAL | - |
| Part 2, Sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986278 Batched method, Dose A | DRUG | Specified dose on specified days |
| BMS-986278 Batched method, Dose B | DRUG | Specified dose on specified days |
| BMS-986278 Continuous method | DRUG | Specified dose on specified days |
Inclusion Criteria: * Healthy female individuals not of childbearing potential (INOCBP) and males, healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory assessment results as determined by the investigator. * Body mass ...
BMS-986278 is an investigational small molecule being developed by Bristol-Myers Squibb Company. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development.
BMS-986278 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 bioavailability study of the compound conducted in the United States.
BMS-986278 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound is investigational and has not been approved by the FDA for any indication.
BMS-986278 has been evaluated in one completed Phase 1 trial, NCT06715683, titled A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants. The trial enrolled 48 healthy volunteers aged 18 years and older in the United States and used a controlled, randomized design.
The Phase 1 trial NCT06715683 evaluated comparative bioavailability of BMS-986278 in healthy participants. It enrolled 48 volunteers, was randomized and controlled, and was not double blinded. The study was conducted in the United States and has been completed.